IMPORTANT! WHY MEDICAL MJ SECTOR WILL GO UP STARTING TODAY! Spicer's Comment WAS VERY POSITIVE. It reaffirms that Trump recognizes the medical use of marijuana (not recreational MJ) although the medical marijuana has not been legalized in all states. It seems that there is great possibility in rescheduling of medical marijuana in federal level.
Some people don't realize how POSITIVE this press release was for the MJ Industry! I LOVE IT!!! This is As Real As It Gets!
First time in HISTORY, the White House acknowledged medical benefits for MJ![/u
OWCP AND ISRAEL WILL LEAD THE WAY[/b]
A MUST READ FROM TECHNOLOGY PROFITS CONFIDENTIAL, I just received the Issue today. Could OWCP be The Next Acquisition Candidate for Teva?? Fellow Investors This Could Be Huge News That Will Be Released by OWCP During The March 1 Conference! Read Below and You Be The Judge. WE Are At The Right Place At The Right Time!
The One Big Pharma That Doesn’t Hate Mary Jane
(Israel) this small country established an early edge in researching medical applications for the cannabis plant.
While the U.S. was banning this plant and severely penalizing its possession, Israel allowed its use in medical research. Only recently has the U.S. Drug Enforcement Administration chosen to allow greater availability of this controlled substance for research.
In contrast, today, some 25,000 Israelis hold medical marijuana permits to help with diseases from cancer to epilepsy.
With a population of just 8 million, not only does Israel have a high percentage of medical users, it also has more stocks listed in the tech- and biotech-heavy Nasdaq than any other country besides the U.S.
Early research, combined with an innovative economy, means that Israel has an edge in finding medical applications for this controversial plant.
And that translates cannabis research into innovative new products — products that better address the needs of patients.
While marijuana will become increasingly important for medical uses, it won’t be a case of “Take two bong rips and call me in the morning.”
As with other drugs, it will be important to deliver a consistent, reliable dose. This not only means using known strains produced under carefully monitored conditions, but also a method for metering the amount of cannabis’ active ingredients.
And that’s exactly what Tel Aviv’s Teva Pharmaceutical (NYSE:TEVA) has been working on bringing to the market.
Teva’s history goes back to the beginning of the 20th century. The modern version of the company, however, emerged when three Israeli pharmaceutical companies merged.
When the FDA approved Teva facilities for generic drug manufacturing, the company gained access to the world’s largest health care market.
Nearly eight in 10 prescriptions are filled by generics. Teva is the world’s largest generics manufacturing company. It is also one of the top 10 pharmas in the world.
But Teva is much more than a generic pharma company. The company maintains a number of research and development facilities worldwide. This year, it will surpass $1.5 billion in research and development investment and help drive the dozens of generic and new drug launches the company intends to complete in 2017.
The FDA currently has a backlog of thousands of generic drugs, which has slowed down Teva’s ability to launch new generic competition. Generic approval waiting times have stretched to nearly two years.
But the incoming administration has made lowering drug prices and FDA reform high priorities. Trump wants to cut the red tape, stating that “There are over 4,000 drugs awaiting approval, and we especially want to speed the approval of lifesaving medications.”
With its ties to Israel’s marijuana research, Teva has a leg up on bringing new products to market. One of these new products is a marijuana inhaler invented in Israel. After signing a deal with a small Israeli medical device company, Teva has received exclusive marketing and distribution rights to a device called the Syqe inhaler.
This device is a pocket-sized cannabis inhaler that uses pre-loaded, childproof cannabis cartridges to deliver the therapeutic benefits of the cannabis.
“The Syqe inhaler,” says the device website, “utilizes selective 100-microgram dosing precision, real-time thermal and flow controllers, lung interfacing and wireless connectivity.” The high level of precision allows patients to attain an optimum balance between symptom relief and psychoactivity by keeping dosing within the therapeutic window.
It is also more efficient than smoking the plant. In clinical trials, the inhaler demonstrated a more than threefold improvement in blood plasma concentration per milligram of drug consumed over smoking.
Unlike other drugs, cannabis is relatively safe. With some drugs, the difference between an effective dose and a deadly one isn’t great. With cannabis, on the other hand, you’d have to consume thousands of times the effective dose to be in danger of death.
But that doesn’t mean dosing doesn’t matter. Patients want to be able to manage their disease symptoms but still be able to drive, work and engage in activities. They don’t necessarily want to sit on the couch all day long. Physicians are also more comfortable prescribing cannabis if they know they can carefully determine and control the dose the patient will receive.
There is good reason to believe the Syqe inhaler is just the beginning of cannabis innovation at Teva. According to Teva Israel CEO Avinoam Sapir, “Teva Israel is entering the field of medical cannabis out of a deep commitment to patients coping with pain, which is one of the company’s core therapeutic areas.”
That could well translate into a global focus using medicines derived from the cannabis plant at Teva. Unlike other big pharmaceutical companies, Teva has shown a much greater willingness to not fight the legalization trend and embrace the use of the plant instead.
And Teva could profit greatly from cannabis-derived medicine. One area of focus at Teva is multiple sclerosis. The company’s best-selling drug is a branded multiple sclerosis therapy.
Cannabis has been studied in this autoimmune disease, and evidence is mounting that cannabinoids help control everything from multiple sclerosis’ pain to involuntary muscle movements. This could well be a future avenue for research…
… and acquisition, as well.
Teva has a long history of creating growth through bold acquisitions, and some cannabis-derived products nearing launch in small biotech and pharma pipelines have blockbuster potential.
•Much success can be attributed to inactivity. Most investors cannot resist the temptation to constantly buy and sell.
•Only buy something that you’d be perfectly happy to hold if the market shut down for 10 years.
Warren Buffett
